NCT03353831

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Completed Phase 3 Last updated 6 April 2025

What this trial tests

Phase 3 trial testing Bevacizumab in Recurrent Ovarian Carcinoma in 574 participants. Completed in 11 March 2025.

Timeline

11 September 2018

Primary endpoint
11 March 2025

11 March 2025

Quick facts

Lead sponsor	AGO Research GmbH
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	574
Start date	11 September 2018
Primary completion	11 March 2025
Estimated completion	11 March 2025
Sites	111 locations across Denmark, France, Finland, Belgium, Austria, Sweden, Estonia, Germany

Drugs / interventions tested

• Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
• Atezolizumab (atezolizumab) — full drug profile →
• Chemotherapy
• Placebos — full drug profile →

Conditions studied

• Recurrent Ovarian Carcinoma — all drugs for Recurrent Ovarian Carcinoma →

Sponsor

AGO Research GmbH — full company profile →

Who can join

18 and older, female only, with Recurrent Ovarian Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after platinum based chemotherapy or 3rd relapse.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
   Moore KN, Bookman M, Sehouli J, Miller A, et al · · 2021 · cited 302× · PMID 33891472 · DOI 10.1200/jco.21.00306
2. Targeting cytokine and chemokine signaling pathways for cancer therapy.
   Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
3. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
   Hack SP, Zhu AX, Wang Y. · · 2020 · cited 223× · PMID 33250900 · DOI 10.3389/fimmu.2020.598877
4. Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy.
   Yang Y, Yang Y, Yang J, Zhao X, et al · · 2020 · cited 168× · PMID 32850861 · DOI 10.3389/fcell.2020.00758
5. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
   Giannone G, Ghisoni E, Genta S, Scotto G, et al · · 2020 · cited 119× · PMID 32575899 · DOI 10.3390/ijms21124414
6. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
   Wang Q, Peng H, Qi X, Wu M, et al · · 2020 · cited 114× · PMID 32728057 · DOI 10.1038/s41392-020-0199-6
7. Tumor Neovascularization and Developments in Therapeutics.
   Katayama Y, Uchino J, Chihara Y, Tamiya N, et al · · 2019 · cited 100× · PMID 30845711 · DOI 10.3390/cancers11030316
8. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
   Haunschild CE, Tewari KS. · · 2020 · cited 72× · PMID 31746224 · DOI 10.2217/fon-2019-0042